Blood
Articles in this Issue
Blocking ANGPT2: from VW disease to vascular normalization
Self-reinforcing IL-1β signaling accelerates the development and recurrence of <i>TCF3</i> :: <i>HLF</i> -positive B-ALL
Abstract The TCF3::HLF fusion protein defines a highly aggressive and incurable subtype of B-cell acute lymphoblastic leukemia (B-ALL). Using a newly established mouse model that f...
A retrospective, real-world study of IV iron use to treat iron deficiency anemia during acute infection
Abstract The administration of IV iron to treat anemia during acute infection remains controversial owing to concerns of exacerbating the infection. We conducted a retrospective co...
No need to wait: treat iron deficiency in the hospital
Multiomic study of cutaneous T-cell lymphoma reveals single-cell clonal evolution in progression and therapy resistance
Abstract Cutaneous T-cell lymphoma (CTCL) remains a challenging disease due to its significant heterogeneity, therapy resistance, and relentless progression. Multiomics technologie...
Defective cerebrovascular development in mice lacking TFPI is restored by activated protein C
Abstract Mice lacking tissue factor pathway inhibitor (Tfpi−/−) succumb to embryonic lethality from excess thrombin production and associated cerebrovascular defects called glomeru...
Funk CR, Wang S, Chen KZ, et al. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. <i>Blood</i> . 2022;139(4):523-537.
No TFPI? APC to the rescue!
IV iron for IDA during acute infection
Thymoma-associated aplastic anemia with concurrent Good syndrome
Von Willebrand factor deficiency impairs angiogenesis via angiopoietin-2: relevance for gut angiodysplasia
Abstract Management of recurrent gastrointestinal (GI) bleeding is a clinical unmet need for patients with von Willebrand disease (VWD) and is linked to the presence of gut vascula...
Can we target CTCL clonal evolution and improve outcomes?
Old drug, new parasite: targeting leukemia with antifungals
Shanmuganathan N, Yeung DT, Wadham C, et al. Impact of <i>ASXL1</i> at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations. <i>Blood</i> . 2025;146(23):2821-2832.
Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy
Abstract Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for hematologic malignancies. The primary nonrelapse complication after allo-HSCT is g...
Revisiting clinical response and refractoriness in immune thrombotic thrombocytopenic purpura
Abstract Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening condition. Caplacizumab substantially shortens the time to clinical response, yet delayed pla...
Orca-T as a force multiplier for HCT immune tolerance
A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia
Abstract Targeting mitochondrial oxidative phosphorylation (OXPHOS) enhances the effects of standard chemotherapy and overcomes treatment resistance in preclinical models of acute...
Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps
Abstract The therapeutic landscape for systemic immunoglobulin light chain (AL) amyloidosis has been revolutionized by daratumumab-based regimens, achieving 76% 5-year overall surv...